Agriflu Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recurring influenza outbreaks, public vaccination campaigns, healthcare awareness programs, hospital based immunization, regulatory approvals for flu vaccines.

The growth in the forecast period can be attributed to aging population growth, expansion of national vaccination schedules, rising healthcare spending, advancements in vaccine formulation, increasing pandemic preparedness initiatives. Major trends in the forecast period include rising demand for seasonal influenza vaccination, expansion of quadrivalent vaccine adoption, increased focus on preventive healthcare, growth of government immunization programs, improved cold chain vaccine distribution.

The rising prevalence of influenza cases is expected to drive the growth of the Agriflu market in the coming years. Influenza, commonly referred to as the flu, is a contagious respiratory disease caused by influenza viruses. The increasing occurrence of influenza is attributed to factors such as expanding global travel, frequent mutation of influenza viruses into new strains, seasonal patterns, limited population immunity, and inadequate vaccination coverage in certain regions. Agriflu offers targeted vaccination for poultry and helps control the spread of avian influenza, thereby reducing viral transmission among birds and minimizing the risk of spillover to humans. This plays an important role in outbreak control and in preventing potential public health threats. For example, in October 2023, according to the World Health Organization, a Switzerland-based health organization, there are approximately one billion cases of seasonal influenza worldwide each year, including 3-5 million cases of severe illness. Therefore, the growing prevalence of influenza is contributing to the expansion of the Agriflu market.

The expansion of immunization programs is also expected to propel the growth of the Agriflu market. Immunization programs are organized public health efforts aimed at protecting individuals and populations from infectious diseases through vaccination. The growth of these programs is driven by increasing awareness of their effectiveness, broader global vaccine coverage, advances in vaccine technologies, heightened concern over public health risks, and the need to protect vulnerable populations such as infants, older adults, and immunocompromised individuals. These programs support the use of targeted vaccines such as Agriflu for poultry, helping to control avian influenza, reduce the risk of zoonotic transmission to humans, and strengthen overall public health efforts to prevent influenza outbreaks. For instance, in January 2024, according to the National Health Service, a UK-based government agency, a new NHS vaccination strategy was introduced with a focus on community-based immunization services and improved outreach to underserved populations. Therefore, the expansion of immunization programs is driving the growth of the Agriflu market.

Government initiatives supporting research and development in healthcare are further expected to boost the growth of the Agriflu market. Government initiatives include policies, programs, and projects implemented by authorities at various levels to address public health challenges and promote innovation. Many governments are increasing investments in healthcare research and development to strengthen disease prevention, vaccine development, and public health infrastructure, which indirectly supports products such as Agriflu. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with growth of 0.9% in 2022. As a result, increasing government support for healthcare research and development is contributing to the growth of the Agriflu market.

Major companies operating in the agriflu market are Sanofi Pasteur S.A.

North America was the largest region in the agriflu market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the agriflu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the agriflu market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the agriflu market by increasing costs related to imported vaccine ingredients, sterile packaging materials, and cold-chain transportation systems. These impacts are more pronounced in government and institutional supply segments that rely on large-scale procurement. Regions dependent on international vaccine sourcing, including parts of europe and asia pacific, face pricing and supply challenges. However, tariffs are encouraging domestic vaccine production and regional manufacturing capacity expansion. This supports long-term supply security and public health resilience.

The agriflu market research report is one of a series of new reports that provides agriflu market statistics, including agriflu industry global market size, regional shares, competitors with a agriflu market share, detailed agriflu market segments, market trends and opportunities, and any further data you may need to thrive in the agriflu industry. This agriflu market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Agriflu is a seasonal influenza vaccine developed to protect against infection caused by the influenza virus. It is generally an inactivated, quadrivalent vaccine that supports the immune system in recognizing and combating influenza viruses.

The main indications for Agriflu include avian influenza (bird flu), foot-and-mouth disease (FMD), classical swine fever (CSF), and other indications. Avian influenza, commonly referred to as bird flu, is a viral infection that mainly affects birds, including wild birds, domestic poultry such as chickens, ducks, and turkeys, and other avian species. The various routes of administration include injectable vaccines and nasal spray vaccines. These products are distributed through channels such as hospitals and clinics, retail and specialty pharmacies, and government and institutional supply systems.

The agiflu market consists of the sale of influenza vaccine therapies, including annual flu shots, nasal sprays, and other immunization treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.